{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:40:00Z","timestamp":1794663600910,"version":"4.9.1"},"reference-count":24,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Outcomes in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab- teserine (Lonca) is an antibody-drug conjugate which was approved by the Food and Drug Administration for the treatment of patients with R\/R DLBCL who have received at least two prior lines of therapy, based on the results of the LOTIS-2 trial. However, there are limited data regarding its efficacy in the real-world setting. This retrospective study included 21 US centers and evaluated outcomes of patients with R\/R DLBCL treated with Lonca. Our analysis comprises 187 patients with notably higher-risk baseline features compared to those of the LOTIS-2 population, including a higher proportion of patients with bulky disease (17% vs. 0%), high-grade B-cell histology (22% vs. 8%), and increased number of prior lines of therapy (median 4 vs. 3). The complete response rate was 14% and overall response rate was 32%. The median event-free survival and overall survival were 2.1 and 4.6 months, respectively. Those with bulky disease and high-grade B-cell histology had significantly worse outcomes, and those with non-germinal center cell of origin and a complete response to the most recent line of therapy demonstrated superior outcomes. In summary, in this largest retrospective cohort study of Lonca in the real-world setting, the response rates, event-free survival and overall survival were lower than those reported in LOTIS-2, which is likely reflective of its use in higher risk and more heavily pre-treated patients in the real world compared to the patients enrolled on a clinical study.<\/jats:p>","DOI":"10.3324\/haematol.2024.285977","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:40:56Z","timestamp":1731555656000},"page":"706-714","source":"Crossref","is-referenced-by-count":7,"title":["Loncastuximab in high-risk and heavily pretreated relapsed\/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers"],"prefix":"10.3324","volume":"110","author":[{"given":"Viktoriya","family":"Zelikson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwath","family":"Gurumurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Annunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Qualls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Amoozgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Challa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Narkhede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Frosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateeha","family":"Furqan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Romancik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Alharthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Bojanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Connor","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwanasha","family":"Merril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Shafagati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"73297","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"73298","doi-asserted-by":"crossref","unstructured":"Hagberg H, Gisselbrecht C, CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006; 17(Suppl 4):iv31-32.","DOI":"10.1093\/annonc\/mdj996"},{"key":"73299","doi-asserted-by":"crossref","unstructured":"Epperla N, Badar T, Szabo A. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019; 3(11):1661-1669.","DOI":"10.1182\/bloodadvances.2019000102"},{"key":"73300","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai W, Alderuccio JP. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021; 22(6):790-800.","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"73301","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Barca EG. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"73302","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke F, Bartlett N. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"73303","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop M, Tam C. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-46.","DOI":"10.1056\/NEJMoa1804980"},{"key":"73304","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba M, Gordon L. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"73305","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387(24):2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"73306","doi-asserted-by":"crossref","unstructured":"Hutchings M, Mous R, Clausen M. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021; 398(10306):1157-1169.","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"73307","doi-asserted-by":"crossref","unstructured":"Prakash R, Subbiah V, Iyer SP. Evolving landscape of antibody drug conjugates in lymphoma. Cancer J. 2022; 28(6):479-487.","DOI":"10.1097\/PPO.0000000000000631"},{"key":"73308","doi-asserted-by":"crossref","unstructured":"Hamadani M, Radford J, Carlo-Stella C. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021; 137(19):2634-2645.","DOI":"10.1182\/blood.2020007512"},{"key":"73309","doi-asserted-by":"crossref","unstructured":"Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Blood. 2022; 140(4):303-308.","DOI":"10.1182\/blood.2021014663"},{"key":"73310","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai W, Alderuccio JP. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024; 109(4):1184-1193.","DOI":"10.3324\/haematol.2023.283459"},{"key":"73311","doi-asserted-by":"crossref","unstructured":"Nordon C, Karcher H, Ankarfeldt MZ. The \u201cefficacy-effectiveness gap\u201d: historical background and current conceptualization. Value Health. 2016; 19(1):75-81.","DOI":"10.1016\/j.jval.2015.09.2938"},{"key":"73312","doi-asserted-by":"crossref","unstructured":"Qualls DA, Lambert N, Caimi PF. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023; 142(26):2327-2331.","DOI":"10.1182\/blood.2023021274"},{"key":"73313","doi-asserted-by":"crossref","unstructured":"Cheson BD, FIsher R, Barring S. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"73314","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36(7):1720-1748.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"73315","doi-asserted-by":"crossref","unstructured":"Choi W, Weisenburger D, Greiner T. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15(17):5494-5502.","DOI":"10.1158\/1078-0432.CCR-09-0113"},{"key":"73316","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Ai W, Radford J. Loncastuximab tesirine in relapsed\/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Adv. 2022; 6(16):4736-4739.","DOI":"10.1182\/bloodadvances.2022007782"},{"key":"73317","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Sehn L. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022; 386(4):351-363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"73318","doi-asserted-by":"crossref","unstructured":"Russler-Germain DA, Cliff ERS, Bartlett NL. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis. Blood. 2023; 142(25):2216-2219.","DOI":"10.1182\/blood.2023022048"},{"key":"73319","doi-asserted-by":"crossref","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019; 16(6):372-385.","DOI":"10.1038\/s41571-019-0184-6"},{"key":"73320","doi-asserted-by":"crossref","unstructured":"Caimi PF, Hamandi M, Carlo-Stella C. In relapsed or refractory diffuse large B\u2010cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. EJHaem. 2023; 5(1):76-83.","DOI":"10.1002\/jha2.816"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11820\/77756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11820\/78115","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11820\/77756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:37Z","timestamp":1794046057000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285977","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}